癌症免疫治疗市场，按治疗类型、按给药途径、按癌症类型、按配销通路、按地理位置

预计2024年全球癌症免疫治疗市场价值为1,410.6亿美元，预计到2031年将达到3,145.3亿美元，2024年至2031年年复合成长率（CAGR）为12.1%。

图 1. 2024 年癌症免疫治疗市场占有率 (%)（按地区）

癌症免疫疗法是一种利用人体自体免疫系统对抗癌症的癌症治疗方法。这是一种创新方法，利用免疫系统的力量并对其进行修改，以增强人体对癌症的自然防御能力。癌症免疫疗法包括单株抗体、检查点抑制剂、白血球介素抑制剂、治疗性癌症疫苗等疗法。随着最近的科学突破提高了对肿瘤细胞与免疫系统之间复杂相互作用的理解，它越来越受到重视。癌症免疫疗法代表了一种新颖的治疗模式，有可能改变未来癌症的治疗方式。

市场动态：

全球癌症免疫治疗市场的成长是由以下因素推动的：全球癌症盛行率不断上升、对有效标靶治疗的需求不断增长以及与传统治疗方式相比，癌症免疫治疗相关的治疗成功率更高。癌症仍然是死亡的主要原因之一，预计全球癌症负担在不久的将来将大幅上升。这极大地促进了免疫疗法的采用。生物技术的进步以及对癌症免疫学的更好理解导致了新型免疫疗法的发展，这为改善患者的治疗结果铺平了道路。然而，与免疫疗法药物相关的高成本、对专业基础设施和医护人员的需求以及与免疫治疗相关的安全问题是限制市场成长的一些挑战。该领域针对新癌症类型的积极研发以及正在进行的临床试验有可能为市场参与者提供成长机会。

研究的主要特点：

• 该报告对全球癌症免疫治疗市场进行了深入分析，并提供了以2023年为基准年的预测期（2024-2031）的市场规模（十亿美元）和年复合成长率（CAGR%）。
• 它阐明了不同细分市场的潜在收入机会，并解释了该市场有吸引力的投资主张矩阵。
• 这项研究还提供了有关市场驱动因素、限制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采取的竞争策略的重要见解。
• 它根据以下参数描述了全球癌症免疫治疗市场的主要参与者——公司亮点、产品组合、主要亮点、财务表现和策略。
• 该报告的见解将使行销人员和公司管理当局能够就未来的产品发布、类型升级、市场扩张和行销策略做出明智的决策。
• 全球癌症免疫治疗市场报告迎合了该行业的各个利益相关者，包括投资者、供应商、产品製造商、分销商、新进业者和财务分析师。
• 利害关係人可以透过用于分析全球癌症免疫治疗市场的各种策略矩阵轻鬆做出决策。

目录

第一章：研究目标与假设

• 研究目标
• 假设
• 缩写

第 2 章：市场范围

• 报告说明
  • 市场定义和范围
• 执行摘要
• Coherent Opportunity Map (COM)

第 3 章：市场动态、法规与趋势分析

• 市场动态
  • 司机
  • 限制
  • 市场机会
• 影响分析
• 市场走向
• 最近的发展
• 收购和合作场景
• 技术概览
• 监管场景
• 定价分析
• PEST分析

第 4 章：全球癌症免疫治疗市场 - 冠状病毒 (COVID-19) 大流行的影响

• 整体影响
• 政府倡议
• COVID-19 对市场的影响

第 5 章：全球癌症免疫治疗市场，按治疗类型，2019 - 2031 年（十亿美元）

• 概述
• 免疫检查点抑制剂
• 疫苗
• 预防疫苗
• 治疗性疫苗
• 过继性细胞疗法
• 肿瘤浸润淋巴细胞（TIL）疗法
• CAR T细胞疗法
• 工程 T 细胞受体 (TCR) 疗法
• 自然杀手（NK）细胞疗法
• 免疫系统调节剂
• 干扰素
• 免疫调节剂 (IMiD)
• 白血球介素
• 单株抗体
• 裸单株抗体
• 缀合单株抗体
• 双特异性单株抗体
• 溶瘤病毒治疗

第 6 章：全球癌症免疫治疗市场，依给药途径划分，2019 - 2031 年（十亿美元）

• 概述
• 皮下
• 口服
• 肌肉注射
• 静脉注射 (IV)
• 其他的

第 7 章：全球癌症免疫治疗市场，按癌症类型，2019 - 2031 年（十亿美元）

• 概述
• 淋巴瘤
• 乳癌
• 大肠直肠癌
• 膀胱癌
• 皮肤癌
• 肺癌
• 肾癌
• 其他的

第 8 章：全球癌症免疫治疗市场，按配销通路，2019 - 2031 年（十亿美元）

• 概述
• 医院药房
• 零售药局
• 网路药局

第 9 章：2019 - 2031 年全球癌症免疫治疗市场（按地区）（十亿美元）

• 介绍
• 北美洲
• 我们
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 拉丁美洲其他地区
• 欧洲
• 英国
• 德国
• 义大利
• 法国
• 西班牙
• 俄罗斯
• 欧洲其他地区
• 亚太地区
• 中国
• 印度
• 日本
• 东协
• 澳洲
• 韩国
• 亚太地区其他地区
• 中东
• 海湾合作委员会
• 以色列
• 中东其他地区
• 非洲
• 北非
• 中非
• 南非

第 10 章：竞争格局

• 公司简介
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Actym Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • Fate Therapeutics
  • AstraZeneca
  • Amgen Inc.
  • GSK plc.
  • Acumen Pharmaceuticals, Inc
  • Arcus Biosciences, Inc.
  • BioNTech SE
  • Cellectis
  • immunitybio inc
  • Autolus Therapeutics
  • ADC Therapeutics SA.
  • Gritstone bio
  • Incyte

第 11 章：分析师建议

• 命运之轮
• 分析师观点
• 连贯的机会图

第 12 章：参考文献与研究方法

• 参考
• 研究方法论

Global cancer immunotherapy market is estimated to be valued at USD 141.06 Bn in 2024 and is expected to reach USD 314.53 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.1% from 2024 to 2031.

Figure 1.Cancer Immunotherapy Market Share (%), By Region, 2024

Cancer immunotherapy is a type of cancer treatment that utilizes the body's own immune system to fight against cancer. It is an innovative approach that harnesses the power of the immune system and modifies it to enhance the body's natural defenses against cancer. Cancer immunotherapy comprises therapies like monoclonal antibodies, checkpoint inhibitors, interleukin inhibitors, therapeutic cancer vaccines and others. It is gaining prominence as recent scientific breakthroughs have improved understanding of the complex interaction between tumor cells and the immune system. Cancer immunotherapy represents a novel treatment paradigm that has the potential to transform the way cancer is treated in the future.

Market Dynamics:

Global cancer immunotherapy market growth is driven by factors such as increasing prevalence of cancer worldwide, rising demand for effective targeted therapies, and higher treatment success rates associated with cancer immunotherapy as compared to conventional treatment modalities. Cancer remains one of the leading causes of mortality and the global burden of cancer is expected to rise significantly in the near future. This is providing a major boost to immunotherapy adoption. Advancements in biotechnology along with better understanding of cancer immunology have led to the development of novel immunotherapies, which are paving the way for improved patient outcomes. However, high costs associated with immunotherapy drugs, need for specialized infrastructure and healthcare personnel, and safety concerns related to immunotherapy are some of the challenges restraining the market growth. Active R&D in this field, targeting new cancer types, and ongoing clinical trials hold potential to provide growth opportunities for market players.

Key Features of the Study:

• This report provides in-depth analysis of the global cancer immunotherapy market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global cancer immunotherapy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Gilead Sciences, Inc., Johnson & Johnson, Actym Therapeutics, Inc., Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Merck & Co., Inc., Fate Therapeutics., AstraZeneca, Amgen Inc., GSK plc., Acumen Pharmaceuticals, Inc, Arcus Biosciences, Inc., BioNTech SE, Cellectis, immunitybio inc, Autolus Therapeutics, ADC Therapeutics SA., Gritstone bio, and Incyte.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global cancer immunotherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cancer immunotherapy market.

Detailed Segmentation-

• Therapy Type:
  • Immune checkpoint inhibitors
  • Vaccines
  • Preventive Vaccines
  • Therapeutic Vaccines
  • Adoptive Cell Therapies
  • Tumor-infiltrating lymphocyte (TIL) therapy
  • CAR T-cell therapy
  • Engineered T-cell receptor (TCR) therapy
  • Natural killer (NK) cell therapy
  • Immune System Modulators
  • Interferons
  • Immunomodulators (IMiDs)
  • Interleukins
  • Monoclonal antibodies
  • Naked monoclonal antibodies
  • Conjugated monoclonal antibodies
  • Bispecific monoclonal antibodies
  • Oncolytic Virus Therapy
• Route of Administration:
  • Subcutaneous
  • Oral
  • Intramuscular
  • Intravenous (IV)
  • Others
• Cancer Type:
  • Lymphoma
  • Breast Cancer
  • Colorectal Cancer
  • Bladder Cancer
  • Skin Cancer
  • Lung Cancer
  • Kidney Cancer
  • Others
• Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Actym Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • Fate Therapeutics.
  • AstraZeneca
  • Amgen Inc.
  • GSK plc.
  • Acumen Pharmaceuticals, Inc
  • Arcus Biosciences, Inc.
  • BioNTech SE
  • Cellectis
  • immunitybio inc
  • Autolus Therapeutics
  • ADC Therapeutics SA.
  • Gritstone bio
  • Incyte

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Therapy Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Cancer Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Market Trends
• Recent Developments
• Acquisitions and Partnerships Scenario
• Technology Overview
• Regulatory Scenario
• Pricing Analysis
• PEST Analysis

4. Global Cancer Immunotherapy Market- Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the market

5. Global Cancer Immunotherapy Market, By Therapy Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Immune checkpoint inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Vaccines
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Preventive Vaccines
• Therapeutic Vaccines
• Adoptive Cell Therapies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Tumor-infiltrating lymphocyte (TIL) therapy
• CAR T-cell therapy
• Engineered T-cell receptor (TCR) therapy
• Natural killer (NK) cell therapy
• Immune System Modulators
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Interferons
• Immunomodulators (IMiDs)
• Interleukins
• Monoclonal antibodies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Naked monoclonal antibodies
• Conjugated monoclonal antibodies
• Bispecific monoclonal antibodies
• Oncolytic Virus Therapy
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Cancer Immunotherapy Market, By Route of Administration, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Intramuscular
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Intravenous (IV)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Cancer Immunotherapy Market, By Cancer Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Lymphoma
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Breast Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Colorectal Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Bladder Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Skin Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Lung Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Kidney Cancer
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Cancer Immunotherapy Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Cancer Immunotherapy Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019-2031
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Therapy Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2019 - 2031, (USD Bn)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Company Profiles
  • Gilead Sciences, Inc.
• Company Overview
• Product Portfolio
• Financial Overview
• Key Highlights
• Market Strategies
  • Johnson & Johnson
  • Actym Therapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Pfizer Inc
  • Novartis AG
  • Merck & Co., Inc.
  • Fate Therapeutics
  • AstraZeneca
  • Amgen Inc.
  • GSK plc.
  • Acumen Pharmaceuticals, Inc
  • Arcus Biosciences, Inc.
  • BioNTech SE
  • Cellectis
  • immunitybio inc
  • Autolus Therapeutics
  • ADC Therapeutics SA.
  • Gritstone bio
  • Incyte

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact